{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:52:36Z","timestamp":1791381156727,"version":"4.3.3"},"reference-count":55,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study aimed to evaluate the effectiveness and safety of cefazolin vs antistaphylococcal penicillins (ASPs) in the treatment of methicillin-susceptible\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      (MSSA) bacteremia. This phase IV, retrospective, comparative-effectiveness, multicenter study used data extracted from the international TriNetX analytics platform. Eligible patients developed monomicrobial MSSA bacteremia during hospitalization between 1 January 2015 and 31 December 2025 and received treatment with either cefazolin or ASPs. The primary outcome was all-cause mortality within 90 days. Safety outcomes included\n                      <jats:italic toggle=\"yes\">Clostridioides difficile<\/jats:italic>\n                      infection within 90 days and renal, liver, allergic, and hematological disorders within 30 days. Survival analyses were conducted after propensity score matching. Among 110,275 patients with MSSA bacteremia identified, 3,908 (3.5%) met the inclusion criteria. After propensity score matching, 1,954 patients were included in each group. Treatment with cefazolin was associated with significantly reduced all-cause mortality within 90 days (9.7% vs 14.7%, HR = 0.620 [0.515\u20130.748]). Among the safety outcomes,\n                      <jats:italic toggle=\"yes\">Clostridioides difficile<\/jats:italic>\n                      infection occurred less frequently in the cefazolin group (4.9% vs 7.20%, HR = 0.631 [0.482\u20130.827]). This real-world evaluation using the international TriNetX database suggests that, compared with ASPs, cefazolin is more effective and safer for the management of MSSA bacteremia.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>CLINICAL TRIALS<\/jats:title>\n                      <jats:p>\n                        This study is registered with ClinicalTrials.gov as\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT07186894\" xlink:type=\"simple\">NCT07186894<\/jats:ext-link>\n                        .\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01765-25","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:07:35Z","timestamp":1789135655000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of cefazolin vs antistaphylococcal penicillins for methicillin-susceptible\n                    <i>Staphylococcus aureus<\/i>\n                    bacteremia: a multicenter real-world evaluation using the international TriNetX database"],"prefix":"10.1128","volume":"70","author":[{"given":"Natesan","family":"Ramsamy","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04vfs2w97","id-type":"ROR","asserted-by":"publisher"}],"name":"CHRU-Nancy, Service des Maladies Infectieuses et Tropicales, Universit\u00e9 de Lorraine","place":["Nancy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3664-226X","authenticated-orcid":true,"given":"Ma\u00efa","family":"Simon","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04vfs2w97","id-type":"ROR","asserted-by":"publisher"}],"name":"D\u00e9partement M\u00e9thodologie Promotion Investigation, Universit\u00e9 de Lorraine, CHRU-Nancy","place":["Nancy, France"]},{"name":"Universit\u00e9 de Lorraine, INSERM, INSPIIRE","place":["Nancy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Adam","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04vfs2w97","id-type":"ROR","asserted-by":"publisher"}],"name":"D\u00e9partement M\u00e9thodologie Promotion Investigation, Universit\u00e9 de Lorraine, CHRU-Nancy","place":["Nancy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Hernandez","sequence":"additional","affiliation":[{"name":"TriNetX LLC","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Williford","sequence":"additional","affiliation":[{"name":"TriNetX LLC","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Denquin","sequence":"additional","affiliation":[{"name":"TriNetX LLC","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-2270","authenticated-orcid":true,"given":"C\u00e9line","family":"Pulcini","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, INSPIIRE","place":["Nancy, France"]},{"id":[{"id":"https:\/\/ror.org\/04vfs2w97","id-type":"ROR","asserted-by":"publisher"}],"name":"CHRU-Nancy, Centre R\u00e9gional en Antibioth\u00e9rapie du Grand Est AntibioEst, Universit\u00e9 de Lorraine","place":["Nancy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9665-2936","authenticated-orcid":true,"given":"Nathalie","family":"Thilly","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04vfs2w97","id-type":"ROR","asserted-by":"publisher"}],"name":"D\u00e9partement M\u00e9thodologie Promotion Investigation, Universit\u00e9 de Lorraine, CHRU-Nancy","place":["Nancy, France"]},{"name":"Universit\u00e9 de Lorraine, INSERM, INSPIIRE","place":["Nancy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0833-0904","authenticated-orcid":true,"given":"Benjamin","family":"Lef\u00e8vre","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04vfs2w97","id-type":"ROR","asserted-by":"publisher"}],"name":"CHRU-Nancy, Service des Maladies Infectieuses et Tropicales, Universit\u00e9 de Lorraine","place":["Nancy, France"]},{"name":"Universit\u00e9 de Lorraine, INSERM, INSPIIRE","place":["Nancy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02185-7"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25460"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2017.1405276"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2505.181733"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.03.015"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05022-11"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.4288"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad525"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac237"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad363"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad500"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.8.3.344"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/379021"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00317-09"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00052-12"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01517-16"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy123"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01106-24"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv319"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000296"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis803"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu296"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-014-0175-8"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.01.007"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.09.001"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad193"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2241-5"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00382-18"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.07.003"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2022.09.021"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae069"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.51353"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf115"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01816-17"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.09.023"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3418-9"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13554"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky259"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.03.010"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-00259-4"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.013"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2025.04.045"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01624-1"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2506905"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035"},{"key":"e_1_3_5_47_2","unstructured":"Compagny overview. 2025. TriNetX. Available from: https:\/\/trinetx.com\/"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00095-17"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0148-z"},{"key":"e_1_3_5_51_2","unstructured":"Stabilis. 2025. Stability in solutions: cefazolin sodium. Available from: https:\/\/www.stabilis.org\/Monographie.php?IdMolecule=113"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2024.105018"},{"key":"e_1_3_5_53_2","unstructured":"Stabilis. 2025. Stability in solutions: cloxacillin. Available from: https:\/\/www.stabilis.org\/Monographie.php?IdMolecule=160"},{"key":"e_1_3_5_54_2","unstructured":"Stabilis. 2025. Stability in solutions: flucloxacillin sodium. Available from: https:\/\/www.stabilis.org\/Monographie.php?IdMolecule=184"},{"key":"e_1_3_5_55_2","unstructured":"Stabilis. 2025. Stability in solutions: oxacillin sodium. Available from: https:\/\/www.stabilis.org\/Monographie.php?IdMolecule=254"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.09.038"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01765-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01765-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:02:20Z","timestamp":1791378140000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01765-25"}},"subtitle":[],"editor":[{"given":"Benjamin P.","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,7]]}},"alternative-id":["10.1128\/aac.01765-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.01765-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"2025-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01765-25"}}